{"id":505353,"date":"2020-09-03T17:52:01","date_gmt":"2020-09-03T17:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=505353"},"modified":"2020-09-03T17:52:01","modified_gmt":"2020-09-03T17:52:01","slug":"warm-autoimmune-hemolytic-anemia-waiha-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/warm-autoimmune-hemolytic-anemia-waiha-market-size-share-trends-epidemiology-forecast-till-2030_505353.html","title":{"rendered":"Warm Autoimmune Hemolytic Anemia (WAIHA) Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"
\"Warm<\/a><\/p>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Warm Autoimmune Hemolytic Anemia (WAIHA) Market Insights, Epidemiology and Market Forecast-2030′ report delivers an in-depth understanding of the disease,historical &forecasted epidemiology as well as the market trends of WAIHAs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.<\/div>\n

Warm Antibody Hemolytic Anemia (WAIHA) is an autoimmune disorder characterized by the premature destruction of healthy red blood cells by autoantibodies. It is a common disorder directed against self RBCs.<\/p>\n

 <\/p>\n

Market Insight<\/strong><\/a><\/p>\n

Warm Autoimmune Hemolytic Anemia  market size in 7MM in 2017wasUSD 368 million  <\/strong><\/a><\/p>\n

Warm Autoimmune Hemolytic Anemia current market does not possess any approved therapy and relies only on the symptomatic treatment alternatives. The management of WAIHA has long been and still is mainly empirical or based on uncontrolled retrospective studies. The treatment landscape is primarily occupied by transfusion and supportive measures, corticosteroids, intravenous immunoglobulin (IVIG), danazol, rituximab, splenectomy, immunosuppressive drugs, and lastly hematopoietic stem cell transplantation (HSCT).<\/p>\n

In a nutshell, it can be summarized that the traditional treatment options for WAIHA include corticosteroids, splenectomy, and conventional immunosuppressive drugs. Over the years, however, newer options have become available with considerable evidence of success.<\/p>\n

They are used mainly in patients who fail to respond to splenectomy, those who relapse after splenectomy, and those who cannot maintain stable hemoglobin levels without unacceptably high doses of corticosteroids. Considering the high unmet medical need and the shortage of approved products, research is ongoing to develop other novel therapies. Although it is too soon to predict their market presence, it can be assumed that the landscape composition will undergo a significant transition in the near future.<\/p>\n

The dynamics of the WAIHA market are anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies, i.e., Fostamitinib (Rigel Therapeutics), APL-2 (Apellis Pharmaceuticals), M281 (Momenta Pharmaceuticals), and few others during the forecast period 2020–2030. <\/p>\n

Warm Autoimmune Hemolytic Anemia Market Drivers<\/strong><\/p>\n